Long COVID-19Phase 2RECOVER-VITALNCT05965726

RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms

A Phase 2 study testing Paxlovid and Ritonavir in people with Long COVID-19 and Long COVID, run by Kanecia Obie Zimmerman at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

Who is it for?: Ages 18 years and older
Conditions the study is for: Long COVID-19, Long COVID
What is being tested?: Paxlovid and Ritonavir
Could I receive a placebo?: Yes, some participants may receive a placebo
How many people: 964 participants
Where: 1 siteUnited States
Study dates: 26 Jul 2023to 13 Mar 2025
Phase: Phase 2
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
No healthy volunteers
Adult, Older adult

See NCT NCT05595369 for RECOVER-VITAL: Platform Protocol level exclusion criteria which applies to this appendix

Additional Appendix Level Exclusion Criteria:

Known pregnancy*
Active or expected breastfeeding during the study
Known eGFR < 30 mL/min
Known severe hepatic impairment (Child-Pugh Class C)
Current use of drugs highly dependent on CYP3A for clearance** and for which elevated concentrations are associated with serious and/or life-threatening reactions and which cannot be interrupted during the time of study administration and within seven days before and after study drug administration
Current use of potent CYP3A inducers** where significantly reduced nirmatrelvir or ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance

A pregnancy test must be performed at the Baseline Visit for participants who are capable of becoming pregnant.
A guide of drugs that may be contraindicated are listed in Section 4 CONTRAINDICATIONS of the Full Prescribing Information of the EUA for PAXLOVID. https://labeling.pfizer.com/ShowLabeling.aspx?id=16474\&format=pdf

Trial locations and contacts

1 site in 1 country.

United States1 site

All sites listed under NCT05595369
Durham, North Carolina, 27710

Other trials in United States

About this study

Official title: RECOVER-VITAL: A Platform Protocol for Evaluation of Interventions for Viral Persistence, Viral Reactivation, and Immune Dysregulation in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

This is an appendix of master protocol (NCT05595369) designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This sub-study is a prospective, multi-center, double-blind, randomized, controlled trial evaluating nirmatrelvir/ritonavir (Paxlovid) in two dosing durations for the treatment of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC). The study is evaluating potential mechanisms of action, efficacy, and safety of antivirals and other therapeutics in individuals with PASC, according to the platform protocol objectives. The hypothesis is that persistent viral infection and/or overactive/chronic immune response and inflammation are underlying contributors to PASC and that antiviral and other applicable therapies may result in viral clearance or decreased inflammation and improvement in PASC symptoms.

Read the detailed description

For this appendix of the master protocol (NCT05595369), participants will be randomized to Paxlovid (nirmatrelvir/ritonavir) vs. ritonavir control plus nirmatrelvir-matching placebo.

When there are multiple study interventions (sub-studies) available under the master protocol (NCT05595369), randomization will occur based on the specific inclusion/exclusion criteria of each appendix.

Conditions: Long COVID-19, Long COVID
Being tested: Paxlovid, Ritonavir, Nirmatrelvir-matching placebo
Keywords: PASC, Paxlovid
Medical subject headings: Post-Acute COVID-19 Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

PaxlovidDrug
Nirmatrelvir 300mg and ritonavir 100mg taken BID (twice a day)
RitonavirDrug
Ritonavir 100mg taken BID (twice a day)
Nirmatrelvir-matching placeboDrug
A nirmatrelvir-matching placebo taken BID (twice a day)

Study groups in NCT05965726
Study group	Role	What they receive
Paxlovid 25 day dosing	Experimental	Paxlovid (nirmatrelvir 300mg, ritonavir 100mg) BID (twice a day) x 25 days Receives: Drug: Paxlovid
Paxlovid 15 day dosing	Experimental	Paxlovid (nirmatrelvir 300mg, ritonavir 100mg) BID (twice a day) x 15 days then ritonavir 100mg plus nirmatrelvir-matching placebo x 10 days Receives: Drug: Paxlovid; Drug: Ritonavir; Drug: Nirmatrelvir-matching placebo
Ritonavir plus nirmatrelvir-matching placebo	Placebo comparator	Ritonavir 100mg plus nirmatrelvir-matching placebo BID (twice a day) x 25 days Receives: Drug: Ritonavir; Drug: Nirmatrelvir-matching placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

Percentage of Participants Who Improved in Cognitive Dysfunction Symptom Cluster, as Measured by Patient-Reported Outcomes Measurement Information System (PROMIS) Cognitive 8a Function T-score
PROMIS Cognitive 8a is a questionnaire assessing self-reported cognitive impairments over the past 7 days using 8 items. It assesses the frequency that respondents experienced cognitive impairments on a scale ranging from 5 (never) to 1 (very often; several times a day). The total raw score is transformed into a T-score, with higher scores representing better cognitive function. The T-scores are interpreted in relation to a US reference population and are scaled to have mean = 50 and SD = 10 in the reference population. The primary endpoint for the cognitive dysfunction symptom cluster is improvement of at least 5 T-score points on the PROMIS-cognitive 8a as measured at Day 90 compared to baseline.
Measured: Baseline, Day 90
Percentage of Participants Who Improved in Autonomic Dysfunction Symptom Cluster, as Measured by the Orthostatic Hypotension Questionnaire (OHQ)
The Orthostatic Hypotension Questionnaire (OHQ) is a patient reported outcome designed to assess the severity and impact of orthostatic hypotension (OH), a condition characterized by a sudden drop in blood pressure when standing. The OHQ consists of two main components: the Orthostatic Hypotension Symptom Assessment (OHSA) and the Orthostatic Hypotension Daily Activity Scale (OHDAS). The OHSA consists of 6 items measuring severity on a scale ranging from 0 (none) to 10 (worst possible). The OHDAS assesses the extent to which OH interferes with daily life on a scale ranging from 0 (no interference) to 10 (total interference). The primary endpoint for the autonomic dysfunction symptom cluster is improvement as defined by at least a 1-point decrease in the response to OHQ question 1 at Day 90 compared to baseline.
Measured: Baseline, Day 90
Percentage of Participants Who Improved in Exercise Intolerance Symptom Cluster, as Measured by the Modified Depaul Symptom Questionnaire-Post Exertional Malaise (DSQ-PEM)
The Modified Depaul Symptom Questionnaire-Post Exertional Malaise (DSQ-PEM) is a patient-reported outcome designed to assess the frequency and severity of symptoms worsening after physical or mental exertion. The first 10 items of DSQ-PEM assess frequency and severity of the following 5 exercise-related impairments. These items were modified for the current study to use a 7-day instead of 6-month look back period. Frequency is rated on a 5-point Likert scale: 0 = none of the time, 1 = a little of the time, 2 = about half the time, 3 = most of the time, and 4 = all of the time. Severity is also rated on a 5-point Likert scale: 0 = symptom not present, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe. The primary endpoint for the exercise symptom cluster is improvement in PEM, defined as having no symptoms of moderate or greater severity with 50% or more frequency as determined by the DSQ-PEM short form at Day 90.
Measured: Baseline, Day 90

Secondary outcomes (7)

Percentage of Participants Who Improved in Cognitive Dysfunction Symptom Cluster, as Measured by a Neurocognitive Battery
The Neurocognitive battery is a performance measure used to assess various elements related to cognition. The neurocognitive battery consists of a cognitive assessment sequence of the following: WHO/UCLA Auditory Verbal Learning Test (WHO/UCLA AVLT) and Symbol Digit Modalities Test (SDMT). The major secondary endpoint for the cognitive dysfunction symptom cluster is a binary endpoint defined as an increase by at least 1 point in either or both of the AVLT delayed recall Z-score and/or SDMT number of correct substitutions Z-score, and no decrease exceeding 0.15 in either of these measures, at Day 90 compared to baseline.
Measured: Baseline, Day 90
Percentage of Participants Who Improved in Autonomic Dysfunction Symptom Cluster, as Measured by the Active Stand Test
The active stand test is performed to assess presence of orthostatic intolerance, orthostatic hypotension, and postural orthostatic tachycardia syndrome. The participant's blood pressure and heart rate are recorded after 5 minutes of lying and then at minutes 1, 3, 5, and 10 after standing. Changes in systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate beats per minute (HR BPM) are assessed from lying to standing for 10 minutes. The major secondary endpoint for the autonomic dysfunction cluster is a binary endpoint defined as improvement in change from lying to standing in at least one of HR, DBP, or DBP from baseline to Day 90 (defined as an increase of at least 10mmHg in SBP, an increase of at least 5mmHg on DBP, or a decrease of at least 10 BPM on HR) and no worsening in any of HR, DBP, or DBP from baseline to Day 90 (defined as any decrease in SBP or DBP, or any increase in HR.
Measured: Baseline, Day 90
Percentage of Participants Who Improved in Exercise Intolerance Symptom Cluster, as Measured by the Endurance Shuttle Walk Test (ESWT)
The endurance shuttle walk test (ESWT) is a performance measure that consists of timed walking on a 10 meter course. The major secondary endpoint for the exercise intolerance symptom cluster is defined as an increase of at least 3 minutes in walk time at Day 90 compared to baseline.
Measured: Baseline, Day 90
Total Number of SAEs (Serious Adverse Events)
Measured: Up to 190 days
Number of Participants Experiencing One or More SAEs (Serious Adverse Events)
Measured: Up to 190 days
Number of Participants Experiencing AEs (Adverse Events) or SAEs (Serious Adverse Events) Leading to Treatment Discontinuation
Measured: Up to 25 days
Number of Participants With an Event of Special Interest (ESI)
Measured: Up to 190 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

26 Jul 202313 Mar 2025

First posted28 Jul 2023
Study start26 Jul 2023
Primary completion5 Dec 2024
Study completion13 Mar 2025

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Other trials for Long COVID-19Studies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 2
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Model description: As part of screening, potential participants will answer symptom questions. Eligible participants will then complete relevant Symptom Cluster assessments at the Screening visit. Participants will subsequently be assigned to one of the three Symptom Clusters based on the assessments. Participants must meet certain criteria within a specific symptom cluster in order to be included in the cluster. After study enrollment and initial cluster assignment, further assessments will be performed. Participants will undergo assessments for the symptom clusters for which the participants qualify.
Masking: Triple blind
Who is masked: Participant, Care provider, Investigator
Enrolment: 964 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT05965726
Sponsor's protocol ID: Pro00111697_A
Other IDs: OTA-21-015G
Acronym: RECOVER-VITAL
Status last verified: Mar 2026
First submitted: 25 Jul 2023
Last updated: 27 Mar 2026
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: Yes
FDA-regulated drug: Yes
FDA-regulated device: No
Individual data sharing: No: The investigators will share the summary of results on the study website: https:// recovercovid.org/

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Not yet recruitingPhase 3
Dapagliflozin for Long COVID Syndrome
COVID - 19, Long COVID Syndrome
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruiting
Long COVID Brain Fog: Cognitive Rehabilitation Trial
Long COVID, Brain Fog
RecruitingPhase 2
SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction
Post-acute Sequelae of COVID-19, Long COVID
Enrolling by invitation
Fareon Open Label Device Clinical Trial
Cognitive Dysfunction, Acquired Brain Injury

All Long COVID-19 trials

Study at a glance

From the registry record, last updated by the sponsor on 27 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: RECOVER-VITAL: A Platform Protocol for Evaluation of Interventions for Viral Persistence, Viral Reactivation, and Immune Dysregulation in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)
ClinicalTrials.gov ID: NCT05965726
Acronym / sponsor ID: RECOVER-VITAL / Pro00111697_A
Conditions: Long COVID-19, Long COVID
Keywords: PASC, Paxlovid
Phase: Phase 2
Study type: Interventional
Recruitment status: Completed
Enrolment: 964 participants (actual)
Lead sponsor: Kanecia Obie ZimmermanUniversity, hospital or other
Study start: 26 Jul 2023 (actual)
Primary completion: 5 Dec 2024 (actual)
Study completion: 13 Mar 2025 (actual)
First posted: 28 Jul 2023 (actual)
Results: Posted 27 Mar 2026

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

For this appendix of the master protocol (NCT05595369), participants will be randomized to Paxlovid (nirmatrelvir/ritonavir) vs. ritonavir control plus nirmatrelvir-matching placebo.

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Triple blind (participant, care provider, investigator)
Number of arms: 3
Model description: As part of screening, potential participants will answer symptom questions. Eligible participants will then complete relevant Symptom Cluster assessments at the Screening visit. Participants will subsequently be assigned to one of the three Symptom Clusters based on the assessments. Participants must meet certain criteria within a specific symptom cluster in order to be included in the cluster. After study enrollment and initial cluster assignment, further assessments will be performed. Participants will undergo assessments for the symptom clusters for which the participants qualify.

Arm	Type	Receives
Paxlovid 25 day dosing	Experimental	Drug: PaxlovidPaxlovid (nirmatrelvir 300mg, ritonavir 100mg) BID (twice a day) x 25 days
Paxlovid 15 day dosing	Experimental	Drug: Paxlovid, Drug: Ritonavir, Drug: Nirmatrelvir-matching placeboPaxlovid (nirmatrelvir 300mg, ritonavir 100mg) BID (twice a day) x 15 days then ritonavir 100mg plus nirmatrelvir-matching placebo x 10 days
Ritonavir plus nirmatrelvir-matching placebo	Placebo comparator	Drug: Ritonavir, Drug: Nirmatrelvir-matching placeboRitonavir 100mg plus nirmatrelvir-matching placebo BID (twice a day) x 25 days

Who may qualify

Ages: 18 years and older
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
PaxlovidNirmatrelvir 300mg and ritonavir 100mg taken BID (twice a day)	Drug	Paxlovid 15 day dosing, Paxlovid 25 day dosing
RitonavirRitonavir 100mg taken BID (twice a day)	Drug	Paxlovid 15 day dosing, Ritonavir plus nirmatrelvir-matching placebo
Nirmatrelvir-matching placeboA nirmatrelvir-matching placebo taken BID (twice a day)	Drug	Paxlovid 15 day dosing, Ritonavir plus nirmatrelvir-matching placebo

Primary outcome

Percentage of Participants Who Improved in Cognitive Dysfunction Symptom Cluster, as Measured by Patient-Reported Outcomes Measurement Information System (PROMIS) Cognitive 8a Function T-score
Time frame: Baseline, Day 90
PROMIS Cognitive 8a is a questionnaire assessing self-reported cognitive impairments over the past 7 days using 8 items. It assesses the frequency that respondents experienced cognitive impairments on a scale ranging from 5 (never) to 1 (very often; several times a day). The total raw score is transformed into a T-score, with higher scores representing better cognitive function. The T-scores are interpreted in relation to a US reference population and are scaled to have mean = 50 and SD = 10 in the reference population. The primary endpoint for the cognitive dysfunction symptom cluster is improvement of at least 5 T-score points on the PROMIS-cognitive 8a as measured at Day 90 compared to baseline.
Percentage of Participants Who Improved in Autonomic Dysfunction Symptom Cluster, as Measured by the Orthostatic Hypotension Questionnaire (OHQ)
Time frame: Baseline, Day 90
The Orthostatic Hypotension Questionnaire (OHQ) is a patient reported outcome designed to assess the severity and impact of orthostatic hypotension (OH), a condition characterized by a sudden drop in blood pressure when standing. The OHQ consists of two main components: the Orthostatic Hypotension Symptom Assessment (OHSA) and the Orthostatic Hypotension Daily Activity Scale (OHDAS). The OHSA consists of 6 items measuring severity on a scale ranging from 0 (none) to 10 (worst possible). The OHDAS assesses the extent to which OH interferes with daily life on a scale ranging from 0 (no interference) to 10 (total interference). The primary endpoint for the autonomic dysfunction symptom cluster is improvement as defined by at least a 1-point decrease in the response to OHQ question 1 at Day 90 compared to baseline.
Percentage of Participants Who Improved in Exercise Intolerance Symptom Cluster, as Measured by the Modified Depaul Symptom Questionnaire-Post Exertional Malaise (DSQ-PEM)
Time frame: Baseline, Day 90
The Modified Depaul Symptom Questionnaire-Post Exertional Malaise (DSQ-PEM) is a patient-reported outcome designed to assess the frequency and severity of symptoms worsening after physical or mental exertion. The first 10 items of DSQ-PEM assess frequency and severity of the following 5 exercise-related impairments. These items were modified for the current study to use a 7-day instead of 6-month look back period. Frequency is rated on a 5-point Likert scale: 0 = none of the time, 1 = a little of the time, 2 = about half the time, 3 = most of the time, and 4 = all of the time. Severity is also rated on a 5-point Likert scale: 0 = symptom not present, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe. The primary endpoint for the exercise symptom cluster is improvement in PEM, defined as having no symptoms of moderate or greater severity with 50% or more frequency as determined by the DSQ-PEM short form at Day 90.

7 secondary outcomes

Percentage of Participants Who Improved in Cognitive Dysfunction Symptom Cluster, as Measured by a Neurocognitive Battery
Time frame: Baseline, Day 90
Percentage of Participants Who Improved in Autonomic Dysfunction Symptom Cluster, as Measured by the Active Stand Test
Time frame: Baseline, Day 90
Percentage of Participants Who Improved in Exercise Intolerance Symptom Cluster, as Measured by the Endurance Shuttle Walk Test (ESWT)
Time frame: Baseline, Day 90
Total Number of SAEs (Serious Adverse Events)
Time frame: Up to 190 days
Number of Participants Experiencing One or More SAEs (Serious Adverse Events)
Time frame: Up to 190 days
Number of Participants Experiencing AEs (Adverse Events) or SAEs (Serious Adverse Events) Leading to Treatment Discontinuation
Time frame: Up to 25 days
Number of Participants With an Event of Special Interest (ESI)
Time frame: Up to 190 days

Results and safety

Results posted to the registry on 27 Mar 2026, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Paxlovid 25 Day Dosing	323	304
Paxlovid 15 Day Dosing	320	297
Ritonavir Plus Nirmatrelvir-matching Placebo	320	304

Primary outcome: Percentage of Participants Who Improved in Cognitive Dysfunction Symptom Cluster, as Measured by Patient-Reported Outcomes Measurement Information System (PROMIS) Cognitive 8a Function T-score

Time frame: Baseline, Day 90. Number (95% Confidence Interval). Unit: percentage of participants

Measure	Paxlovid 25 Day Dosing n = 110	Paxlovid 15 Day Dosing n = 121	Ritonavir Plus Nirmatrelvir-matching Placebo n = 101
Value	57.8 (48.2 to 67.4)	52.4 (43.2 to 61.5)	54.6 (44.8 to 64.4)

Paxlovid 25 Day Dosing vs Ritonavir Plus Nirmatrelvir-matching Placebo: Difference: 3.2 (95% CI -10.4 to 16.8), p = 0.646, G-computation
Paxlovid 15 Day Dosing vs Ritonavir Plus Nirmatrelvir-matching Placebo: Difference: -2.2 (95% CI -15.5 to 11.1), p = 0.742, G-computation
Paxlovid 25 Day Dosing vs Paxlovid 15 Day Dosing: Difference: 5.4 (95% CI -7.8 to 18.6), p = 0.420, G-computation

Population analysed: Modified Intent to Treat population (the population that was randomized, received at least part of 1 dose of study intervention or control and who are eligible, enrolled and randomized into a symptom cluster) with PROMIS cognitive 8a function data collected.

Primary outcome: Percentage of Participants Who Improved in Autonomic Dysfunction Symptom Cluster, as Measured by the Orthostatic Hypotension Questionnaire (OHQ)

Time frame: Baseline, Day 90. Number (95% Confidence Interval). Unit: percentage of participants

Measure	Paxlovid 25 Day Dosing n = 121	Paxlovid 15 Day Dosing n = 103	Ritonavir Plus Nirmatrelvir-matching Placebo n = 110
Value	63.1 (54.7 to 71.5)	69.4 (60.5 to 78.3)	69.5 (60.7 to 78.3)

Paxlovid 25 Day Dosing vs Ritonavir Plus Nirmatrelvir-matching Placebo: Difference: -6.4 (95% CI -18.5 to 5.7), p = 0.303, G-computation
Paxlovid 15 Day Dosing vs Ritonavir Plus Nirmatrelvir-matching Placebo: Difference: -0.1 (95% CI -12.5 to 12.3), p = 0.988, G-computation
Paxlovid 25 Day Dosing vs Paxlovid 15 Day Dosing: Difference: -6.3 (95% CI -18.3 to 5.8), p = 0.307, G-computation

Primary outcome: Percentage of Participants Who Improved in Exercise Intolerance Symptom Cluster, as Measured by the Modified Depaul Symptom Questionnaire-Post Exertional Malaise (DSQ-PEM)

Time frame: Baseline, Day 90. Number (95% Confidence Interval). Unit: percentage of participants

Measure	Paxlovid 25 Day Dosing n = 112	Paxlovid 15 Day Dosing n = 105	Ritonavir Plus Nirmatrelvir-matching Placebo n = 114
Value	25.5 (17.3 to 33.6)	34.2 (25.2 to 43.3)	33.3 (24.8 to 41.8)

Paxlovid 25 Day Dosing vs Ritonavir Plus Nirmatrelvir-matching Placebo: Difference: -7.8 (95% CI -19.5 to 3.8), p = 0.186, G-computation
Paxlovid 15 Day Dosing vs Ritonavir Plus Nirmatrelvir-matching Placebo: Difference: 0.9 (95% CI -11.4 to 13.2), p = 0.884, G-computation
Paxlovid 25 Day Dosing vs Paxlovid 15 Day Dosing: Difference: -8.8 (95% CI -20.8 to 3.3), p = 0.155, G-computation

7 secondary outcomes are reported in the full results.

Adverse events

Time frame: Up to 190 days. Other adverse events reported at 0% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Paxlovid 25 Day Dosing	13 of 323 (4%)	212 of 323 (65.6%)	0 of 323
Paxlovid 15 Day Dosing	13 of 320 (4.1%)	203 of 320 (63.4%)	0 of 320
Ritonavir Plus Nirmatrelvir-matching Placebo	16 of 320 (5%)	180 of 320 (56.3%)	0 of 320

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 27 Mar 2026.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Individual participant dataSharing planned: No. The investigators will share the summary of results on the study website: https:// recovercovid.org/

Related trials for Long COVID-19

Not yet recruitingPhase 3
Dapagliflozin for Long COVID Syndrome
COVID - 19, Long COVID Syndrome
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruiting
Long COVID Brain Fog: Cognitive Rehabilitation Trial
Long COVID, Brain Fog
RecruitingPhase 2
SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction
Post-acute Sequelae of COVID-19, Long COVID
Enrolling by invitation
Fareon Open Label Device Clinical Trial
Cognitive Dysfunction, Acquired Brain Injury

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

The record lists no contact. Use the official record to reach the sponsor.

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Paxlovid and Ritonavir in people with Long COVID-19 and Long COVID, run by Kanecia Obie Zimmerman at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 27 Mar 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants Who Improved in Cognitive Dysfunction Symptom Cluster, as Measured by Patient-Reported Outcomes Measurement Information System (PROMIS) Cognitive 8a Function T-score (time frame: Baseline, Day 90). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05965726.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Mar 2026.